Track Equillium, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Equillium, Inc. EQ · Stock Open Equillium, Inc. in new tab

1.30 USD
EPS
-0.14
P/B
1.61
ROE
-58.98
Beta
2.04
Target Price
8.56 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-0.14
Book Value0.88
Price to Book1.61
Debt/Equity1.04
% Insiders15.999%
Growth
Revenue Growth0.37%
Estimates
Forward P/E-5.99
Forward EPS-0.24
Target Mean Price8.56

DCF valuation

Model fair value for Equillium, Inc. (EQ)
Result
Sign in to run the valuation for EQ.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus None · mean target 8.56 USD (low 4.00, high 20.00) · as of 12 Nov 2026
Low 4.00
Mean 8.56
High 20.00
Price 1.30
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Equillium, Inc. Logo Equillium, Inc. Analysis (EQ)

United States Health Care Official Website Stock

Is Equillium, Inc. a good investment? Equillium, Inc. (EQ) is currently trading at 1.30 USD. Market analysts have a consensus price target of 8.56 USD. This suggests a potential upside from current levels.

Earnings Schedule: Equillium, Inc. is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -0.24.

Investor FAQ

Does Equillium, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Equillium, Inc.?

Equillium, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -0.14.

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Exchange Ticker
LSE (United Kingdom) 0A4D.L
FRA (Germany) 0FY.F
NMS (United States) EQ
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion